Cell therapy with autologous mesenchymal stem cells for premature baby with neonatal sepsis and bronchopulmonary dysplasia: Case report

Background: Mesenchymal stem cells (MSCs) have significant regenerative and anti-inflammatory potential; therefore they are widely used in medical practice. Neonatology is becoming a new area of clinical application of MSCs, including pathology treatment of premature newborns. Objective: In the presented case report are demonstrated the results of cell therapy of bronchopulmonary dysplasia (BPD) with autologous MSCs in premature newborns who have suffered from neonatal sepsis. Methods: The patient was conducted with two intravenous injections of biomedical cellular product (BMCP) "Human mesenchymal stem cells” in addition to standard treatment. Results: The presented clinical case demonstrates the effectiveness of autologous umbilical cord MSCs in the medical prevention of severe forms of BPD. The immunomodulatory effect of umbilical cord MSCs provided a favorable outcome of early onset neonatal sepsis (EONS). Conclusion: The inclusion of autologous MSCs in the therapy of premature babies with neonatal sepsis and developing BPD is a safe and effective treatment.